News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xechem International (XKEM) Forms Xechem UK Ltd. (XKEM.OB); Files Orphan Drug Application In European Union (EU) For Its Sickle Cell Disease (SCD) Drug



10/19/2005 5:09:11 PM

NEW BRUNSWICK, N.J.--(BUSINESS WIRE)--Aug. 30, 2005--Xechem International, Inc. (OTC BB: XKEM) Xechem International today announced the formation of Xechem UK Ltd., a wholly owned subsidiary based in the UK. Dr. Ramesh Pandey, Chairman and CEO of Xechem International and Managing Director, Xechem UK, stated "The European market is now composed of 25 nations with a population of approximately 450 million people. This population will grow over time and represents even a larger opportunity than the US. Xechem UK will facilitate Xechem's entry into the European market for NICOSAN(TM)/HEMOXIN(TM), its lead product for Sickle Cell Disease (SCD)."

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES